Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales
Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors
You may also be interested in...
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.